Efficacy of Yinzhihuang Granules and Entecavir on Hepatitis B-induced Cirrhosis

[Objectives]This study aimed to observe the efficacy and safety of Yinzhihuang granules and entecavir in the treatment of hepatitis B-induced cirrhosis.[Methods]Total 80 patients with decompensated hepatitis B-induced cirrhosis were evenly and randomly divided into two groups,treatment group and control group.The patients in the treatment group were given orally with 0.25 mg entecavir and 5000 mg Yinzhihuang granules once a day,and those in the control group were given orally with 0.5 mg entecavir once a day.The levels of aspartate aminotransferase(AST),alanine aminotransferase(ALT),hyaluronic acid(HA)and HBV DNA,the Child-Pugh score,and the positive situation of HBeAg in different groups were observed before treatment and 12,24,48 and 96 weeks after the treatment,respectively.[Results]The serum ALT,AST,HA and HBV DNA levels,the HBeAg positive rate,and the Child-Pugh score in the treatment and control groups were significantly improved after the treatment(P<0.05).The improvement of the above indicators in the treatment group at week 96 was significantly better than that in the control group(P<0.05).[Conclusions]The combination of Yinzhihuang granules and entecavir is superior to entecavir in the treatment of decompensated hepatitis B-induced cirrhosis.

Protective Effects of Yinzhihuang Combined with Metformin on Nonalcoholic Fatty Liver Diseases Based on PPAR-αSignaling Pathway

[Objectives]To explore the protective effects and mechanism of Yinzhihuang combined with metformin on nonalcoholic fatty liver diseases(NAFLD)based on PPAR-αsignaling pathway.[Methods]54 male SD rats were randomly divided into 2 groups,namely normal group(12 rats)and high-fat feed group(42 rats).After 8 weeks,2 rats were randomly selected from each group.After pathological examination confirmed the success of the NAFLD model,the high-fat feed group was divided into model group,Yinzhihuang(9000 mg/kg),metformin group(200 mg/kg),Yinzhihuang combined with metformin group(4500 mg/kg+100 mg/kg),10 rats in each group.Except the normal group and the model group,the other groups were given treatment drugs at the same time,one time a day,on the fifth weekend of the experiment,at the last time of administration,fasting but giving water for 16 h,then collected blood and liver tissue.Biochemical method was used to detect AST and ALT in serum and SOD,MDA,GSH-px biochemical indicators in liver tissue;enzyme-linked immunosorbent assay(ELISA)was used to detect the levels of TNF-α,IL-6 and TGF-βin liver tissue;Western blot was used to detect the expression of peroxisome proliferators-activated receptor-α(PPAR-α)protein in rat liver tissue.[Results]Compared with the model group,the serum levels of ALT,AST and MDA in liver tissue of model group rats were significantly increased;the levels of SOD and GSH-px in liver tissue were significantly increased;TNF-αand IL-6 and TGF-βcontents in liver tissue were significantly increased.[Conclusions]Both Yinzhihuang and metformin have a therapeutic effect on NAFLD rats,and the effect of combined application of the two is significantly better than the intervention effect of Yinzhihuang or metformin alone,the mechanism is possibly associated with the regulation of PPAR-αsignaling pathway.

Effects of Yinzhihuang oral liquid and albumin on bilirubin, inflammatory factors, immune indexes and related factors in neonatal pathologic jaundice

Objective: To explore the effects of Yinzhihuang oral liquid and albumin on bilirubin, inflammatory factors, immune indexes and related factors in neonatal pathologic jaundice. Methods: A total of 134 neonates with pathologic jaundice admitted to our hospital from May 2017 to April 2018 were randomly selected as the control group (n=67) and the observation group (n=67), the control group was treated with albumin, the observation group was treated with Yinzhihuang Oral Liquid on the basis of the control group. The bilirubin, inflammatory factors, immune indicators, alpha-fetoprotein (AFP) and transferrin (TRF) were compared and analyzed before and after treatment. Results: After treatment, the levels of TBIL, DBIL and IBIL in both groups were significantly lower than those before treatment (P<0.05), and the levels of TBIL, DBIL and IBIL [(118.60±10.85) μmol/L, (6.95±1.52) μmol/L, (115.30±14.20)μmol/L] in observation group were significantly lower than those in control group;the levels of CRP and IL-6 in both groups were significantly lower than those before treatment (P<0.05), and the levels of CRP and IL-6 [(8.26±2.07) mg/L, (12.69±2.15) pg/mL] in observation group were significantly lower than those in control group (P<0.05);the levels of CD4+, CD4+/CD8+ in both groups were significantly higher than those before treatment (P<0.05), while the levels of CD8+ was significantly lower than that before treatment, the levels of CD4+, CD4+/CD8+ [(47.08±5.70)%, (2.08±0.41)] in observation group were significantly higher than those in control group (P<0.05), and the level of CD8+ [(22.90±2.05)%] was significantly lower than that in control group (P<0.05);the levels of AFP in significantly higher than before treatment (P<0.05), and the levels of AFP [(12.69±3.04)mg/L] in observation group were significantly lower than those in control group (P<0.05), the levels of TRF [(2.02±0.35) g/L] were significantly higher than those in control group (P<0.05). Conclusions: The combination of Yinzhihuang oral liquid and albumin can effectively reduce the bilirubin level in neonatal jaundice, inhibit its inflammatory reaction, enhance the cellular immune function and improve the expression of AFP and TRF, which is of clinical significance.

Study on the mechanism of Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules for neonatal jaundice treatment

Objective:To observe the mechanism of Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules for neonatal jaundice treatment and offer clinical help to neonatal jaundice treatment. Methods:80 children with neonatal jaundice were selected and randomly divided into groups:the observation group (40 children) and the control group (40 children). The patient in the control group were treated with blue light and the patients in the observation group were treated with Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules. Biochemical parameters [TBA (total bile acid), TSB (serum total bilirubin), DB (Direct bilirubin) and TCB (Percutaneous jaundice index)], nerve factor [NSE (neuronspecific enolase), Aβ(βamyloid protein) and S100B (Astrocyte derived protein)] and myocardial enzyme spectrum [LDH (lactate dehydrogenase), CK (creatine kinase) and CK-MB (isoenzymes of creatine kinase)], liver function [ALT (Alanine aminotransferase) and AST (glutamic-oxalacetic transaminase)] and renal function (BUN and Cr) were detected and analyzed before and after treatment. Results:The comparison of Biochemical parameters, nerve factor and myocardial enzymes, liver function and renal function in the two groups before treatment were not statistically significant (P>0.05). Biochemical parameters (TBA, TSB, TCB and DB), nerve factor (NSE, Aβand S100B) and myocardial enzyme spectrum (LDH, CK and CK-MB), liver function (ALT and AST) and renal function [BUN (urea nitrogen) and Cr (creatinine)] in both groups after treatment significantly decreased compared with that before treatment. The changes were statistically significant (P<0.05). Biochemical parameters (TBA, TSB, TCB and DB), nerve factor (NSE, Aβand S100B) and myocardial enzyme spectrum (LDH, CK and CK-MB), liver function (ALT and AST) and renal function (BUN and Cr) in observation group after treatment decreased more significantly compared with that in control group. The difference between two groups was considered to be statistically significant (P<0.05). Conclusions:Yinzhihuang granules, Blue light irradiation combined with Bifid Triple Viable Capsules could regulate the Biochemical parameters, protect nerve function and cardiac muscle cells and improve liver and kidney function in newborns with jaundice. So it has a very important clinical significance of the treatment to neonatal jaundice.

茵栀黄颗粒与双歧杆菌四联活菌片联用对新生儿高胆红素血症的治疗效果

目的探讨茵栀黄颗粒联合双歧杆菌四联活菌片对新生儿高胆红素血症的治疗效果。方法选取120例高胆红素血症新生儿随机分为参照组(n=60)和联合组(n=60)。参照组仅接受蓝光照射治疗,联合组在参照组基础上采用茵栀黄颗粒联合双歧杆菌四联活菌片治疗,均持续治疗5 d。比较两组的临床疗效、血胆红素水平、黄疸消退时间及不良反应。结果联合组治疗总有效率为95.00%,高于参照组的83.33%(P<0.05)。治疗5 d后,联合组血清总胆红素、结合胆红素水平低于参照组,黄疸消退时间短于参照组(P<0.05)。两组的不良反应发生率比较无统计学差异(P>0.05)。结论茵栀黄颗粒与双歧杆菌四联活菌片联用治疗新生儿高胆红素血症效果显著,可明显降低患儿的血胆红素水平,加快黄疸消退且安全性较高。

茵栀黄口服液联合间断蓝光照射治疗新生儿高胆红素血症的临床效果分析

目的探讨茵栀黄联合间断蓝光治疗新生儿高胆红素血症的临床疗效。方法简单随机选取2021年1月—2022年12月丰县人民医院收治的新生儿病理性黄疸100例为研究对象,根据随机数表法分成两组,各50例,对照组采取蓝光治疗,观察组采取蓝光联合茵栀黄治疗,比较两组临床疗效、中医症候评分、血清胆红素水平及不良反应发生率。结果观察组疗效为96.00%,高于对照组的80.00%,差异有统计学意义(χ^(2)=4.640,P=0.031);治疗后,观察组的血清的中医症候评分低于对照组,差异有统计学意义(P<0.05)。观察组患者治疗后的血清胆红素水平低于对照组,差异有统计学意义(P<0.05);治疗期间两组的不良反应的发生率比较,差异无统计学意义(P>0.05)。结论茵栀黄口服液联合间断蓝光照射治疗新生儿高胆红素血症可提高治疗效果,促进胆红素排泄,改善临床症状,且安全性高。

茵栀黄颗粒治疗3610例黄疸患者的真实世界临床联合用药特征分析

目的对真实世界进行定向数据挖掘,针对茵栀黄颗粒治疗黄疸的临床方案特征进行分析,探索茵栀黄颗粒治疗黄疸的联合用药方案。方法从真实世界15家医院信息系统(hospital information system,HIS)中提取3610例使用茵栀黄颗粒治疗黄疸患者的个人、住院及用药情况,标准化数据后以关联规则数据挖掘方式得出临床中使用茵栀黄颗粒治疗黄疸的联合用药方案;结果3610例患者各年龄段均有发病,以45~65岁占比最多(1242例,占34.40%),均为男性多于女性。联合用药情况:茵栀黄颗粒主要联用西药胸腺肽、地塞米松、甘草酸、苯巴比妥、奥美拉唑、中药柴胡注射液、感冒清热颗粒、苦黄注射液、康复新液、结核丸,用药类别为西药抗菌药、肝胆疾病治疗药、免疫促进药,中药解表剂、清热剂、扶正剂。常见一般性黄疸治疗用药方案:茵栀黄颗粒+苦黄注射液+甘草酸;茵栀黄颗粒+甘草酸+胸腺肽+苦黄注射液;抗结核药物相关肝损害所致黄疸协同治疗用药方案:茵栀黄颗粒+结核丸+康复新液+乙胺丁醇;茵栀黄颗粒+吡嗪酰胺+利福平+乙胺丁醇+康复新液;常见的用药类别联合方案:茵栀黄颗粒+清热剂+肝、胆疾病治疗药;茵栀黄颗粒+肝、胆疾病治疗药+免疫促进药+抗菌药+清热剂;茵栀黄颗粒+解表剂+清热剂+抗菌药;茵栀黄颗粒+扶正剂+解表剂+清热剂+抗菌药。结论治疗一般性黄疸,临床常采用的治疗方案为茵栀黄颗粒联合苦黄注射液+甘草酸和茵栀黄颗粒联合苦黄注射液+甘草酸+胸腺肽;对于长期服用抗结核药物引起的黄疸,常用的治疗方案为茵栀黄颗粒联合结核丸+康复新液+乙胺丁醇和茵栀黄颗粒联合吡嗪酰胺+利福平+乙胺丁醇+康复新液。

Clinical Observation of Yinzhihuang Oral Liquid(茵栀黄口服液) on Prevention of the Premature Infantile Jaundice

Objective:To observe the clinical efficacy of Yinzhihuang Oral Liquid(YOL,茵栀黄口服液)to prevent the premature infantile jaundice.Methods:After excluded hemolytic,suffocation,infection,and the very low birth weight,242 cases of premature infants were randomly assigned to two groups,the treatment group and the control group.Both groups were taken conventional procedures,such as warmth,feeding,and blood glucose monitoring,and the treated group was administered YOL 5 mL each time,twice daily additionally,and the co...

茵栀黄口服液对蓝光照射联合布拉氏酵母菌散治疗新生儿黄疸的增效作用

目的评估茵栀黄口服液对蓝光照射联合布拉氏酵母菌散治疗新生儿黄疸的增效作用。方法回顾性分析义乌市中心医院2022年1月至2024年1月收治的新生儿黄疸确诊患儿资料,根据治疗方案分为试验组与对照组。比较两组患儿心肌功能[肌酸激酶同工酶(CK-MB)、肌酸激酶(CK)、心肌钙蛋白I(cTnI)]、血气指标[氧分压(PaO_(2))、二氧化碳分压(PaCO_(2))、pH值]、症状改善情况、疗效及不良反应。结果研究共纳入180例患儿,每组各90例。试验组有效率高于对照组,且不良反应发生率低于对照组(P<0.05)。治疗后,两组患儿CK、CK-MB、cTnI、PaCO_(2)水平较治疗前降低,且试验组低于对照组(P<0.05);两组患儿pH值、PaO_(2)水平增加,且试验组高于对照组(P<0.05)。试验组各症状改善时间和日均大便次数均小于对照组(P<0.05)。结论茵栀黄口服液联合布拉氏酵母菌散能有效改善新生儿黄疸确诊患儿心肌功能,调节血气,提高患儿疗效,且安全性较高。

茵栀黄口服液联合蓝光、头孢哌酮钠舒巴坦钠治疗新生儿感染性黄疸的临床疗效

目的:探讨茵栀黄口服液联合蓝光、头孢哌酮钠舒巴坦钠治疗新生儿感染性黄疸的临床疗效。方法:选取2021年6月至2023年6月杞县妇幼保健院收治的94例感染性黄疸新生儿作为研究对象,随机数字表法分为茵栀黄联合组和常规治疗组,各47例。常规治疗组采用常规的蓝光照射和头孢哌酮钠舒巴坦钠抗感染治疗;茵栀黄联合组在常规治疗的基础上联合茵栀黄口服液治疗。治疗7 d后,比较两组临床总有效率、黄疸消退时间、住院时间、胆红素下降值、神经行为能力[新生儿神经行为测定评分系统(Neonatal behavioral neurological assessment,NBNA)]、免疫球蛋白(Immunoglobulin,Ig)A、IgG水平、胆红素相关指标[血清白蛋白(Albumin,ALB)、非结合胆红素(Unconjugated bilirubin,UCB)、总胆红素(Total bilirubin,TBIL)水平]及不良反应发生率。结果:治疗后,茵栀黄联合组总有效率明显高于常规治疗组(P<0.05);茵栀黄联合组黄疸消退时间、住院时间明显短于常规治疗组,每日胆红素下降值明显大于常规治疗组(P<0.05);茵栀黄联合组血清IgA、IgG水平及NBNA评分均明显高于常规治疗组(P<0.05);茵栀黄联合组ALB、UCB、TBIL水平均明显低于常规治疗组(P<0.05);两组不良反应发生率无明显差异(P>0.05)。结论:茵栀黄口服液联合蓝光、头孢哌酮钠舒巴坦钠治疗新生儿感染性黄疸疗效显著,可进一步缩短黄疸消退的时间,降低胆红素相关指标水平,提高患儿免疫功能和神经行为能力,加快患儿康复进程。

经络抚触配合茵栀黄颗粒对新生儿高胆红素血症血清乳酸脱羟酶和神经元特异性烯纯化酶及胱抑素C水平的影响

目的探讨经络抚触配合茵栀黄颗粒对新生儿高胆红素血症血清乳酸脱羟酶(LDH)、神经元特异性烯纯化酶(NSE)、胱抑素C(CysC)水平的影响。方法选取2019年1月至2021年12月德兴市人民医院收治的80例新生儿高胆红素血症患儿作为研究对象,按就诊时间分为研究组与对照组,每组40例。两组均接受常规对症治疗,在此基础上,对照组给予茵栀黄颗粒治疗,研究组给予经络抚触配合茵栀黄颗粒治疗。比较两组血清总胆红素(TBiL)水平、临床疗效、血清LDH、NSE、CysC水平及生长发育指标。结果治疗后,研究组血清TBiL水平低于对照组,差异有统计学意义(P<0.05)。研究组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清LDH、NSE、CysC水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组体质量重于治疗前,奶摄入量、大便次数均多于治疗前,睡眠时间长于治疗前,且研究组体质量重于对照组,奶摄入量、大便次数均多于对照组,睡眠时间长于对照组,差异有统计学意义(P<0.05)。结论经络抚触配合茵栀黄颗粒治疗新生儿高胆红素血症治疗效果更佳,可显著降低血清TBiL、LDH、NSE、CysC水平,促进患儿生长发育。

茵栀黄口服液联合双歧杆菌四联活菌治疗新生儿黄疸的效果

目的分析茵栀黄口服液联合双歧杆菌四联活菌应用在新生儿黄疸中的效果。方法选择山东省梁山县人民医院儿科自2021年6月至2023年10月期间收治的80例黄疸儿作为观察对象,依据随机数字表法进行分组,即对照组(40例,双歧杆菌四联活菌)和观察组(40例,茵栀黄口服液联合双歧杆菌四联活菌),对比两组不同治疗方案的作用效果。结果治疗后,其观察组的黄疸消失时间、胆红素及大便恢复正常时间等指标均优于对照组,(P<0.05);观察组治疗总有效率为97.50%显著高于对照组的85.00%,两组间差异明显(P<0.05);比较两组的并发症情况,观察组的并发症例数有2例,占比5.00%,对照组的并发症发生例数有9例,占比22.50%,组间差异显著(P<0.05)。结论茵栀黄口服液联合双歧杆菌四联活菌在新生儿黄疸中均有较高的应用价值,不仅提高了临床治疗效果,还促进其临床症状的改善,其不良反应也有所降低,可加速其康复进度。

茵栀黄颗粒结合酪酸梭菌活菌散治疗新生儿病理性黄疸临床研究

目的研究茵栀黄颗粒结合酪酸梭菌活菌散治疗新生儿病理性黄疸临床效果。方法研究纳入新生儿病理性黄疸总计142例(2021年2月—2023年2月收治),将患儿以随机数字表法分为观察组与对照组,各组71例,入组患儿均给予蓝光照射治疗,对照组患儿同时采取酪酸梭菌活菌散治疗,观察组患儿在对照组治疗基础上结合茵栀黄颗粒治疗,各组患儿数据观察:治疗效果、治疗前后血清胆红素水平变化及中医症候积分(面目皮肤发黄、不欲吮乳、唇干、小便深黄、大便白如陶土等)变化、黄疸消退时间及住院时间、免疫功能指标变化、不良反应。结果观察组患儿与对照组总有效率比较(97.18%vs88.73%),P<0.05;治疗前,各组患儿血清总胆红素(Total bilirubin,TBil)及间接胆红素(Indirect bilirubin,IBil)、结合胆红素(Bound bilirubin,DBil)等胆红素指标、中医症候积分(面目皮肤发黄、不欲吮乳、唇干、小便深黄、大便白如陶土等)、CD^(+)_(4)T淋巴细胞、CD^(+)_(8)T淋巴细胞、CD^(+)_(4)/CD^(+)_(8)等比较,P>0.05,治疗后各组患者TBil、IBil、DBil、中医症候积分(面目皮肤发黄、不欲吮乳、唇干、小便深黄、大便白如陶土等)等指标均下降,CD^(+)_(4)、CD^(+)_(4)/CD^(+)_(8)均上升,观察组患儿治疗后TBil、IBil、DBil、中医症候积分(面目皮肤发黄、不欲吮乳、唇干、小便深黄、大便白如陶土等)等指标低于对照组,CD^(+)_(4)、CD^(+)_(4)/CD^(+)_(8)等指标高于对照组,P<0.05;与对照组患儿黄疸消退时间及住院时间比较,观察组患儿各项时间均更短,P<0.05;两组患儿不良反应率均较低,P>0.05。结论茵栀黄颗粒结合酪酸梭菌活菌散治疗新生儿病理性黄疸临床效果显著,患儿症状改善,恢复快,患儿免疫功能改善,且治疗安全性高,值得应用。

茵栀黄口服液联合蓝光照射对病理性黄疸新生儿胆红素、心肌损害指标的影响

目的:探讨茵栀黄口服液联合蓝光照射对病理性黄疸新生儿胆红素、心肌损害指标的影响。方法:选取2023年1-12月在本院进行治疗的病理性黄疸新生儿90例,随机数字表法分为对照组和观察组各45例,对照组给予蓝光照射治疗,观察组给予蓝光照射加用茵栀黄口服液治疗,比较两组临床疗效、胆红素[总胆红素(TBIL)、直接胆红素(DBIL)、间接胆红素(IBIL)]、炎性因子[肿瘤坏死因子-α(TNF-α)、C反应蛋白(CRP)、白细胞介素-6(IL-6)]、心肌损害指标[肌酸肌酶同工酶(CK-MB)、心肌肌钙蛋白(cTnI)]、神经功能损害指标[β-定粉酶样蛋白(Aβ)、神经元特异性烯醇化酶(NSE)、TBIL与白蛋白比值(B/A)]及不良反应。结果:观察组治疗有效率(93.3%)高于对照组(77.8%),胎便排空时间、黄疸消退和住院时间均短于对照组(均P<0.05)。治疗1周后,两组血清TBIL、DBIL、IBIL、TNF-α、CRP、IL-6、CK-MB、cTnI、Aβ、NSE、B/A水平均降低,且观察组各指标均低于对照组(均P<0.05)。不良反应发生率观察组(6.7%)与对照组(11.1%)无差异(P>0.05)。结论:蓝光照射联合茵栀黄口服液治疗病理性黄疸新生儿疗效提高,可促进患儿黄疸消退,降低胆红素、cTnI水平,保护心肌细胞和神经功能,有利于改善预后。

清肝化湿活血汤加减联合茵栀黄颗粒治疗酒精性肝病临床观察

目的探讨清肝化湿活血汤加减联合茵栀黄颗粒治疗酒精性肝病的临床疗效。方法选取医院2021年3月至2023年3月收治的酒精性肝病患者200例,按随机数字表法分为观察组和对照组,各100例。两组患者均予酒精性肝病的基础治疗,对照组患者加用茵栀黄颗粒,观察组患者在对照组治疗基础上加用清肝化湿活血汤加减。两组患者均治疗12周。结果观察组总有效率为91.00%,显著高于对照组的79.00%(P<0.05)。治疗后,观察组患者肋痛胀满、痞块结坚、乏力纳呆、舌红苔黄的中医证候积分均显著低于对照组(P<0.05);观察组患者的丙氨酸氨基转移酶、天门冬氨酸氨基转移酶、碱性磷酸酶、总胆红素水平均显著低于对照组(P<0.05);观察组患者的肝门静脉血流动力学指标最大流速、平均流速、搏动指数均显著高于对照组(P<0.05),阻力指数显著低于对照组(P<0.05);观察组患者的血清炎性因子白细胞介素17A、前列腺素E_(2)、CXC趋化因子配体13水平均显著低于对照组(P<0.05);观察组患者的欧洲研究与治疗组织生活满意度测定量表(EORTCQLQ-C30)躯体功能、角色功能、社会功能、总体健康评分均显著高于对照组(P<0.05)。治疗期间,观察组和对照组不良反应发生率相当(12.00%比8.00%,P>0.05)。结论清肝化湿活血汤加减联合茵栀黄颗粒治疗酒精性肝病的临床疗效良好,可改善患者的中医证候积分和肝功能、肝门静脉血流动力学指标,降低炎性因子水平,且安全性良好。

茵栀黄口服液联合蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗新生儿黄疸临床研究

目的:观察茵栀黄口服液联合蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗新生儿黄疸的疗效,并分析该联合疗法对患儿肝功能的影响。方法:回顾性分析100例新生儿黄疸患儿的临床资料,按照不同治疗方案分为常规治疗组和茵栀黄治疗组各50例。常规治疗组予以蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗;茵栀黄治疗组在常规治疗组基础上给予茵栀黄口服液口服治疗。2组均治疗7 d。比较2组临床疗效、住院时间、胎便排空时间及不良反应发生情况,比较2组治疗前后胆红素和肝功能指标水平。结果:茵栀黄治疗组总有效率96.00%,高于常规治疗组84.00%(P<0.05)。治疗后,2组血清直接胆红素(DBil)、间接胆红素(IBil)、总胆红素(TBil)水平均下降(P<0.05),且茵栀黄治疗组低于常规治疗组(P<0.05)。治疗后,2组血清谷氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)及碱性磷酸酶(ALP)水平均降低(P<0.05),且茵栀黄治疗组低于常规治疗组(P<0.05)。茵栀黄治疗组患儿的住院时间、胎便排空时间均短于常规治疗组(P<0.05)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论:采用茵栀黄口服液联合蓝光照射及枯草杆菌肠球菌二联活菌散剂治疗新生儿黄疸能够提高临床疗效,保护患儿肝功能,降低胆红素水平和不良反应的发生。

A Study of the Mechanism of Yinzhihuang（菌栀黄）Injection in the Treatment of Infantile Hepatitis Syndrome

The content of serum total bilirubin, serum alanine aminotransferase and hepatic enlarge-ment were observed before and affer the treatment for intantile hepatitis syndrome by using injections ofYinzhihuang. Peripheral blood T cell subproportions and levels of duodenal bilirubin were also detected insome patients. The results of this study suggest the injections of Yinzhihuang had a significant effect in re-solving jaundice, but no effect in improving the disturbance of cellular immunity.

茵栀黄口服液联合双歧杆菌四联活菌片治疗新生儿黄疸的效果及对免疫功能的影响

目的研究茵栀黄口服液联合双歧杆菌四联活菌片治疗新生儿黄疸的效果及对血清总胆汁酸(TBA)与免疫功能的影响。方法选取2021年10月至2022年11月收治的110例黄疸新生儿为研究对象,按照随机数字表法将其分为对照组和观察组,各55例。对照组采用双歧杆菌四联活菌片治疗,观察组在对照组基础上联合茵栀黄口服液治疗。比较两组的治疗效果。结果观察组的治疗总有效率高于对照组(P<0.05)。观察组的药物起效时间、黄疸消退时间、胎便排空时间短于对照组,大便次数多于对照组(P<0.05)。治疗后,观察组的TBA、直接胆红素(DBIL)、总胆红素(TBIL)、间接胆红素(IBIL)水平低于对照组(P<0.05)。治疗后,观察组的CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论茵栀黄口服液联合双歧杆菌四联活菌片治疗黄疸患儿的效果确切,可缓解临床症状,降低TBA水平,增强免疫功能。

茵栀黄颗粒联合蓝光照射治疗湿热熏蒸型新生儿黄疸的临床疗效观察

目的探讨茵栀黄颗粒联合蓝光照射对湿热熏蒸型新生儿黄疸的疗效。方法选取商丘市第四人民医院2021年12月至2022年12月收治的90例新生儿黄疸患儿,按照随机数字表法分为观察组和对照组,各45例。对照组采用蓝光照射,观察组在蓝光照射基础上加用茵栀黄颗粒,两组均连续治疗14d。比较两组临床指标、中医证候积分、胆红素水平、肝功能指标及不良反应。结果观察组临床指标改善均优于对照组,差异均有统计学意义(P<0.05);治疗前两组各项中医证候积分、血清总胆红素(TBIL)、间接胆红素(IBIL)水平、血清总胆汁酸(TBA)、γ-谷氨酰转移酶(γ-GT)、碱性磷酸酶(AKP)水平差异无统计学意义(P>0.05),治疗后两组各项中医证候积分、血清TBIL、IBIL水平、血清TBA、γ-GT、AKP水平均降低,且观察组低于对照组,差异均有统计学意义(P<0.05);观察组不良反应发生率低于对照组,差异具有统计学意义(P<0.05)。结论茵栀黄颗粒联合蓝光照射可有效缓解新生儿黄疸临床症状,降低胆红素水平,改善肝功能,疗效确切且安全性较高。

茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗新生儿感染性黄疸的临床效果

目的探讨茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗新生儿感染性黄疸的临床效果。方法选取伊犁哈萨克自治州奎屯医院2020年1月至2022年12月的80例新生儿感染性黄疸患儿作为研究对象,按照随机数字表法分为对照组和观察组,每组各40例。对照组采用哌拉西林钠他唑巴坦钠治疗,观察组采用茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗。比较两组临床疗效、黄疸指数和心肌酶谱指标及不良反应发生情况。结果观察组临床总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清总胆红素、乳酸脱氢酶、总胆汁酸、肌酸激酶同工酶和经皮测胆红素水平均降低,且观察组水平低于对照组,差异有统计学意义(P<0.05)。两组不良反应发生情况比较,差异无统计学意义(P>0.05)。结论茵栀黄颗粒联合哌拉西林钠他唑巴坦钠治疗新生儿感染性黄疸的临床效果较好,值得推广。